Urokinase-type plasminogen activator receptor (uPAR) as a therapeutic target in cancer

Urokinase-type plasminogen activator receptor (uPAR) is an attractive target for the treatment of cancer, because it is expressed at low levels in healthy tissues but at high levels in malignant tumours. uPAR is closely related to the invasion and metastasis of malignant tumours, plays important rol...

Full description

Saved in:
Bibliographic Details
Published in:Journal of translational medicine 2022-03, Vol.20 (1), p.135-135, Article 135
Main Authors: Zhai, Bing-Tao, Tian, Huan, Sun, Jing, Zou, Jun-Bo, Zhang, Xiao-Fei, Cheng, Jiang-Xue, Shi, Ya-Jun, Fan, Yu, Guo, Dong-Yan
Format: Article
Language:English
Subjects:
Cancer
Care and treatment
Cell receptors
Gene therapy technologies
Health aspects
Humans
Monoclonal antibody therapy
Nanoparticles (NPs)
Neoplasms - therapy
Oncolytic virotherapy
Photodynamic therapy (PDT)/photothermal therapy (PTT)
Physiological aspects
Prognosis
Receptors, Urokinase Plasminogen Activator - genetics
Receptors, Urokinase Plasminogen Activator - metabolism
Review
Signal Transduction
Urokinase
Urokinase-Type Plasminogen Activator - genetics
Urokinase-Type Plasminogen Activator - metabolism
Urokinase-type plasminogen activator receptor (uPAR)
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Urokinase-type plasminogen activator receptor (uPAR) is an attractive target for the treatment of cancer, because it is expressed at low levels in healthy tissues but at high levels in malignant tumours. uPAR is closely related to the invasion and metastasis of malignant tumours, plays important roles in the degradation of extracellular matrix (ECM), tumour angiogenesis, cell proliferation and apoptosis, and is associated with the multidrug resistance (MDR) of tumour cells, which has important guiding significance for the judgement of tumor malignancy and prognosis. Several uPAR-targeted antitumour therapeutic agents have been developed to suppress tumour growth, metastatic processes and drug resistance. Here, we review the recent advances in the development of uPAR-targeted antitumor therapeutic strategies, including nanoplatforms carrying therapeutic agents, photodynamic therapy (PDT)/photothermal therapy (PTT) platforms, oncolytic virotherapy, gene therapy technologies, monoclonal antibody therapy and tumour immunotherapy, to promote the translation of these therapeutic agents to clinical applications.
ISSN:1479-5876
1479-5876
DOI:10.1186/s12967-022-03329-3